Jie Li

Dr. Jie Li


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2021 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
JLJie Li
Jie Li
XWXiaozi Wang
Xiaozi Wang
CMChuanbao Ma
Chuanbao Ma
SXShasha Xu
Shasha Xu
MXMengyao Xu
Mengyao Xu
LXLiying Xue
Liying Xue
Acute myelogenous leukemia (AML) is frequently accompanied by a poor prognosis. The majority of patients with AML will experience recurrence due to multiple drug resistance. Our previous study reported that targeting the mTOR pathway may increase cell sensitivity to doxorubicin (Doxo) and provide an improved therapeutic approach to leukemia. However, the effect and mechanism of action of NVP‑BEZ235 (BEZ235), a dual inhibitor of PI3K/mTOR, on Doxo‑resistant K562 cells (K562/A) is yet to be elucidated. Therefore, the aim of the present study was to investigate the effects of BEZ235 on K562/A cell proliferation. K562/A cells was investigated using CCK‑8, flow cytometry and western blotting, following BEZ235 treatment. It was observed that BEZ235 significantly decreased the viability of K562/A cells. In addition, BEZ235 arrested K562/A cells at the G0/G1 phase, and reduced the protein expression levels of CDK4, CDK6 and cyclin D1. Apoptotic cells were more frequently detected in K562/A cells treated with BEZ235 compared with the control group (12.97±0.91% vs. 7.37±0.42%, respectively; P<0.05). Cells treated with BEZ235 exhibited downregulation of Bcl‑2 and upregulation of Bax. Furthermore, BEZ235 treatment markedly decreased the activation of the PI3K/AKT/mTOR pathway and its downstream effectors. Thus, these results demonstrated that BEZ235 inhibited cell viability, induced G0/G1 arrest and increased apoptosis in K562/A cells, suggesting that BEZ235 may reverse Doxo resistance in leukemia cells. Therefore, targeting the PI3K/mTOR pathway may be of value as a novel therapeutic approach to leukemia.

9 July 2019 in Oncology Letters
Verified
Journal Article
Open access
PDF file
JLJie Li
Jie Li
WLWenjing Liu
Wenjing Liu
HHHongling Hao
Hongling Hao
QWQiuyi Wang
Qiuyi Wang
LXLiying Xue
Liying Xue
Chronic myelogenous leukemia (CML) is a common hematological malignancy. Some patients progressing to the blast phase develop chemotherapeutic drug resistance. In the authors' previous study, it was found that the mammalian target of rapamycin (mTOR) pathway was activated in CML and that rapamycin inhibited the proliferation of K562 cells. Targeting the mTOR pathway may be used in combination with chemotherapeutic drugs to enhance their efficacy and overcome multidrug resistance. The aim of the present study was to investigate the effects of rapamycin and doxorubicin on K562 cell proliferation following the combination treatment, and further focus on confirming whether rapamycin enhanced the antitumor effects of doxorubicin by downregulating the mTOR/ribosomal protein S6 kinase (p70S6K) pathway. It was found that rapamycin and doxorubicin significantly decreased the viability of K562 cells. The apoptotic cells were more frequently detected in rapamycin and doxorubicin treatment groups (25.50±1.25%). Both drugs decreased Bcl‑2 and increased Bax expression in K562 cells. Rapamycin and doxorubicin also reduced the phosphorylation levels of mTOR and p70S6K. Meanwhile, p70S6K‑targeting small interfering (si)RNA and doxorubicin inhibited cell proliferation and regulated key factors of the cell cycle. In addition, the exposure of cells to p70S6K siRNA and doxorubicin significantly increased cell apoptosis, as compared with single treatment. These results suggested that rapamycin could enhance the antitumor effects of doxorubicin on K562 cells by downregulating mTOR/p70S6K signaling. Targeting the mTOR/p70S6K pathway may be a new therapeutic approach for leukemia.

17 July 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
XWXiaoning Wang
Xiaoning Wang
JGJiashuo Guo
Jiashuo Guo
YLYan Liu
Yan Liu
NZNa Zheng
Na Zheng
SXShaohan Xu
Shaohan Xu
JLJie Li
Jie Li
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematological malignancy with a highly aggressive behavior and median survival of <2 years. Especially, most BPDCN patients present with extensive and non-specific skin lesions, usually leading to misdiagnosis as a skin disease and delay therapy. As for treatment, most patients with BPDCN experience relapse shortly after treatment with the traditional regimens. The alleviation of skin symptoms reflects the effects of clinical treatments. Herein, we report a case of a 71-year-old man with intermittent and gradually expanding skin lesions over his chest, abdomen, and back for 1 year. On admission, physical examination revealed extensive skin lesions and multiple enlarged lymph nodes. Laboratory examinations showed pancytopenia and numerous malignant cells in the peripheral blood smear (60%), bone marrow aspirate smear (73.5%). Immunophenotyping using flow cytometry and immunohistochemistry presented large numbers of BPDCN cells in the bone marrow, cervical lymph nodes and dermal tissue. PET/CT revealed multiple enlarged lymph nodes and splenomegaly. Once the diagnosis was identified as BPDCN, the patient began treatment with the oral BCL2 inhibitor venetoclax and subcutaneously administered azacitidine. After the first course, skin lesions reduced markedly and complete remission was achieved in the bone marrow. Our study and current cumulative data according to reviewing systematically suggest that venetoclax combined with azacitidine is safe, effective, and applicable in the treatment of BPDCN, especially for elderly relapsed/refractory patients. This study, therefore, significantly contributes to the literature on the current and future treatment for BPDCN.

5 March 2025 in Cancer Reports
Verified
Journal Article
Open access
XGXiao‐Han Gao
Xiao‐Han Gao
JYJun Yuan
Jun Yuan
XZXiao‐Xia Zhang
Xiao‐Xia Zhang
RWRui‐Cang Wang
Rui‐Cang Wang
JYJie Yang
Jie Yang
JLJie Li
Jie Li
Background: The investigation of cuproptosis in relation to tumor development has been limited, particularly in multiple myeloma (MM), indicating the need for further research. Our study aimed to examine the impact of cuproptosis‐related genes (CRGs) on the prognosis of MM.Methods: Using the datasets, we filtered cuproptosis score‐related differentially expressed genes (CRDEGs) by overlapping the DEGs between the MM and normal groups and between the high and low cuproptosis score groups. Additionally, key module genes were identified through weighted gene co‐expression network analysis. A univariate Cox algorithm and multivariate Cox analysis were employed to obtain biomarkers of MM and build a prognostic model before conducting independent prognostic analysis.Results: A total of 59 CRDEGs were filtered, demonstrating their involvement in the COPII vesicle coat and endoplasmic reticulum protein processing, and protein processing in the endoplasmic reticulum. Six prognosis‐related biomarkers (PARP1, EDEM3, SEC23A, RSL24D1, TTC37, and SRP72) were obtained, and a prognostic model was developed. The performance of the model was verified using a test cohort (GSE136324 dataset) and a validation cohort (GSE24080 dataset). Risk score, age, albumin, International Staging System (ISS) score, and β2‐microglobulin (B2M) were found to be significant predictors of prognosis independently.Conclusion: As a result of this investigation, a set of six biomarkers associated with cuproptosis (PARP1, EDEM3, SEC23A, RSL24D1, TTC37, and SRP72) were screened to provide a basis for predicting the prognosis of MM.

2 October 2020 in Medicine
Verified
Journal Article
Open access
JLJie Li
Jie Li
XWXiao-Zi Bs Wang
Xiao-Zi Bs Wang
RWRui-Cang Wang
Rui-Cang Wang
JYJie Yang
Jie Yang
HHHong-Ling Hao
Hong-Ling Hao
LXLiying Xue
Liying Xue
Introduction: Henoch–Schönlein purpura (HSP) is an extremely rare condition in patients with pulmonary tuberculosis, with only a few reported cases. Compared to patients with typical clinical symptoms, it is difficult to make a definitive diagnosis when HSP presents as an initial manifestation in pulmonary tuberculosis patients. Herein, a case of pulmonary tuberculosis that showed HSP at first was reported, and the related literatures were reviewed. Patient Concerns: A 24-year-old man presented with palpable purpura on the extremities, accompanied by abdominal pain, bloody stools, and knee pain. Diagnoses: The patient was diagnosed with pulmonary tuberculosis based on the results of interferon gamma release assays, purified protein derivative test, and computed tomography. Interventions: The patient was treated with vitamin C and chlorpheniramine for 2 weeks, and the above-mentioned symptoms were relieved. However, 3 weeks later, the purpura recurred with high-grade fever and chest pain during the inspiratory phase. The patient was then treated with anti-tuberculosis drugs, and the purpura as well as the high fever disappeared. Outcomes: The patient recovered well and remained free of symptoms during the follow-up examination. Conclusion: Pulmonary tuberculosis presenting with HSP as an initial manifestation is not common. Therefore, it is difficult to clinically diagnose and treat this disease. When an adult patient shows HSP, it is important to consider the possibility of tuberculosis to avoid misdiagnosis and delayed treatment.

3 April 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LXLiying Xue
Liying Xue
SGShuting Gou
Shuting Gou
YZYu Zhang
Yu Zhang
RYRuirui Yuan
Ruirui Yuan
CDChang Dong
Chang Dong
JLJie Li
Jie Li
Objective: Esophageal carcinoma (ESCA) is one of the most common malignant diseases and contributes to the annual burden of death worldwide. A better understanding of the underlying molecular changes is urgently required to identify early diagnostic biomarkers and effective therapeutics. The chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTMs) is reported to be entangled in many human cancers. However, the role of CMTMs in ESCA remains unclear. Methods: The differential expressions of CMTMs between ESCA and normal tissues were analyzed using TCGA database. The relationships between CMTMs and immune infiltration in the tumor microenvironment (TME) were also evaluated to explore their underlying values in the diagnosis and prognosis of ESCA. Results: The results showed that ESCA showed significantly higher expressions of CMTM1,3,6,7 and lower expressions of CMTM4,5 than normal tissue (P < 0.05). Meanwhile, CMTM3,4,8 expressions were correlated with the tumor stage of ECSA patients. The analysis on immune infiltrations (CD8 + T, Tregs, NK and macrophages) showed that M2 macrophages was dominant in TME, with significantly higher levels than the other cells (F = 326.93, P < 0.001). The higher abundance of M2 macrophages and Tregs significantly shortened the survival time of patients with ESCA (P = 0.01). Interestingly, the expression levels of CMTM1,3,5,7 were comparable to the abundance of M2 macrophages (CMTM1: r = 0.172168; CMTM3: r = 0.313221; CMTM5: r = 0.130669; CMTM7: r = 0.119922; P < 0.05). CMTM2,4,5,7,8 positively correlated with Tregs (P < 0.05). Moreover, we found positive associations between the expression of CMTMs and the signatures of M2 macrophages (MS4A4A, VSIG4 and CD163). Conclusion: There were differential expressions of CMTMs between ESCA and normal tissues. Furthermore, the expression of CMTMs was positively correlated with M2 macrophages, indicating a possibility that CMTMs may become a new immunotherapy target for ESCA.